🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’ve entered into a definitive agreement to acquire Intera Oncology, a medical device company that provides a solution to treat metastatic colorectal cancer in the liver. Upon close, we look forward to welcoming the Intera Oncology team! bit.ly/410Xekc

We are guided by our commitment to enhance the quality of patient care. Every success story shared at our Everyone Makes an Impact (EMAI) events begins with our dedicated employees who make a difference in millions of lives. #AdvancingTogether

CMS approved Transitional Pass-Through Payment (TPT) for AGENT DCB effective January 1, 2025. This will support coronary DCB adoption and improve patient access to this new technology. Learn more: bit.ly/4gvUeRh

We’ve agreed to acquire @BoltIVL, developer of an intravascular lithotripsy (IVL) offering to treat coronary and peripheral disease, which will expand our cardiovascular portfolio with a complementary & differentiated calcium modification platform. bit.ly/3DXLmG3 $BSX

In an interview with CNBC Jim Cramer, CEO Mike Mahoney shares how breakthrough products are transforming healthcare and driving strong business performance: "We’re coming off a great 2023, better 2024 and we aim to have a terrific 2025 and beyond." youtu.be/UxvSrXN-KGg #JPM25

“Everything we do is about making sure we advance care for patients around the world suffering from urological conditions,” says Meghan Scanlon, SVP and president, Urology. She shares how our acquisition of Axonics will help us do just that. bit.ly/40K5QLw

We have officially closed the acquisition of Cortex. We look forward to advancing the OptiMap™ System developed by Cortex which complements our electrophysiology portfolio with a differentiated cardiac mapping offering to assist with complex atrial fibrillation cases.

Tomorrow morning we’ll host a conference call & webcast to discuss Q4 & FY 2024 financial results. Tune in here: bit.ly/4gtPkUL $BSX

Boston Scientific announces results for Q4 & FY 2024: bit.ly/4jDAVYV $BSX

Tune in now: bit.ly/40MJ8kB $BSX

ICYMI, here are a few key takeaways from our earnings announcement: bit.ly/4aQPmVw

Further expansion of our cardiovascular portfolio includes today’s announcement that we’ve agreed to acquire SoniVie, developer of an intravascular ultrasound system designed to perform renal artery denervation for the treatment of hypertension. bit.ly/3XoenBP

We have officially closed the acquisition of @BoltIVL. We look forward to advancing the intravascular lithotripsy (IVL) therapy developed by Bolt which will complement our cardiovascular portfolio by expanding treatment options for coronary and peripheral disease. $BSX

Tomorrow morning we’ll host a conference call & webcast to discuss Q1 2025 financial results. Tune in here: bit.ly/3Ezxumc $BSX

Boston Scientific announces results for Q1 2025: bit.ly/3EAUi54 $BSX

Tune in now: bit.ly/3GkMyVn $BSX

ICYMI, here are a few key takeaways from our earnings announcement: bit.ly/42DhgAw

We’ve closed the acquisition of Intera Oncology, provider of the Intera 3000 Hepatic Artery Infusion Pump and floxuridine. We look forward to adding this technology to our portfolio and advancing treatment for patients with liver cancer.

We’ve officially closed the acquisition of SoniVie, adding its investigational, ultrasound-based TIVUS™ system to our cardiovascular portfolio. This renal denervation technology holds promise for advancing hypertension care through a minimally invasive approach.

The Special Olympics USA Games announced today that Boston Scientific will be an official sponsor of the USA Games, as well as the Official Softball Sponsor of the 2026 USA Games.🏅 Thank you for the support. Read more ➡️ 2026specialolympicsusagames.org/news/boston-sc… #CallingAllChampions